Follicular lymphoma trials in Japan
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Where
- Chiba, Okayama, Tokyo
- Age
- 18 years and over
- People
- 215 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00 - Phase 1Taking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Chiba, Okayama, Tokyo
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - Phase 3Taking peopleA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Where
- Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto, Kurashiki-shi, Kyoto, Minatoku, Okayama, Osaka, Sapporo, Sunto-gun, Toyoake-shi, Yamagata, Yokohama
- Age
- 18 years to 130 years
- People
- 1,018 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01 - Phase 1Taking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 2Taking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Chiba, Kashiwa, Kōtoku, Nagoya, Yokohama
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Chūōku, Kashiwa
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Where
- Chūō, Chuo Ku, Fukuoka, Himeji, Hiroshima, Morioka, Nagoya, Sapporo, tabashi City
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00